Tubridge Flow-diverting Stent
Commercial- Indications
- Hemorrhagic stroke
Company intelligence / Profile preview
MicroPort NeuroScientific has commercialized over 21 neuro-interventional medical devices in China with 14 additional pipeline products at various development stages. Its portfolio includes innovative solutions for both ischemic and hemorrhagic strokes. The company’s NUMEN coil system has received regulatory approvals in the US (FDA), EU (CE Mark), South Korea (MFDS), Brazil, Japan, among others. Clinical adoption continues to expand globally with strong revenue growth reported.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MicroPort NeuroScientific.